ROCKVILLE, Md., March
6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:
RGNX), a leading clinical-stage biotechnology company seeking to
improve lives through the curative potential of gene therapy based
on its proprietary NAV® Technology Platform, today
announced that it will participate in the following March investor
conferences:
Barclays Global Healthcare
Conference
Date: Wednesday, March 13, 2019
Location: Loews Miami Beach Hotel, Miami, FL
Fireside chat: Wednesday, March 13, 2019 at
2:35 p.m. ET
Morgan Stanley Healthcare Corporate Access
Day
Date: Tuesday, March 19, 2019
Location: Boston Harbor Hotel at Rowes Wharf,
Boston, MA
A live webcast of the Barclays fireside chat can be accessed in
the Investors section of REGENXBIO's website at www.regenxbio.com.
An archived replay of the webcast will be available on the same
website for approximately 30 days following the presentation. In
addition, REGENXBIO senior management will be holding one-on-one
meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACT:
Investors:
Heather
Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen,
212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-300807331.html
SOURCE REGENXBIO Inc.